| Company/Division name | TCR2 Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 175 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 3.75 |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | T cell receptor Fusion Construct T cells, gavo-cel |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Skilled workforce availability/training, Under-utilized capacity, Other, import replacement |
